Anti-hyperlipidemic effects of 500 mg spilanthol (SA3X) supplementation in people with dyslipidemia – a randomized, parallel-group placebo-controlled trial
Author:
Mishra Kumar Guru1ORCID, Patnaik Nabnita2ORCID, Pradhan Nihar Ranjan3ORCID
Affiliation:
1. Department of Community Medicine , Apollo Institute of Medical Sciences and Research , Hyderabad , India 2. Department of Obstetrics and Gynecology , 596687 AIIMS Bibinagar , Hyderabad , India 3. Department of Vascular and Endovascular Surgery , AIG Hospitals , Hyderabad , India
Abstract
Abstract
Objectives
Dyslipidemia is a critical risk factor for cardiovascular disease. This study investigated the impact of 500 mg of spilanthol (SA3X) supplementation on lipid profiles in men with dyslipidemia using a randomized, parallel-group, placebo-controlled design.
Methods
A total of 279 male participants were randomly allocated to one of four groups: SA3X without exercise, placebo without exercise, SA3X with exercise, and placebo with exercise. After a one-month control period, participants received SA3X capsules or placebo for three months. The exercise groups undertook standardized weight-lifting exercises four times weekly. Lipid profiles, biochemical parameters, and anthropometric measurements were monitored throughout and after the intervention.
Results
Both SA3X groups exhibited significant reductions in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) compared to the placebo groups. By day 90, the SA3X-no-exercise group showed a 16.78 % decrease in TC, while the SA3X-plus-exercise group demonstrated a 52.87 % decrease compared to placebo. Significant reductions in TG and LDL-C were noted at days 60 and 90 (p=0.01 and p=0.03, respectively). The SA3X-plus-exercise group also exhibited decreased random blood sugar levels at days 60 and 90 compared to placebo-plus-exercise. Moreover, decreases in C-reactive protein, creatine kinase, and serum creatinine levels were observed.
Conclusions
SA3X supplementation, particularly when combined with exercise, effectively improved lipid profiles and various health markers in men with dyslipidemia. Adverse events, primarily taste disturbance, were mild. These findings suggest SA3X may be a promising adjunctive therapy for managing dyslipidemia, emphasizing its potential cardiovascular health benefits and supporting further investigation.
Trial registration
CTRI/2021/05/033694; May 2021.
Publisher
Walter de Gruyter GmbH
Reference37 articles.
1. Hedayatnia, M, Asadi, Z, Zare-Feyzabadi, R, Yaghooti-Khorasani, M, Ghazizadeh, H, Ghaffarian-Zirak, R, et al.. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis 2020;19:42. https://doi.org/10.1186/s12944-020-01204-y. 2. Tsao, CW, Aday, AW, Almarzooq, ZI, Alonso, A, Beaton, AZ, Bittencourt, MS, et al.. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation 2022;145:e153–639. https://doi.org/10.1161/CIR.0000000000001074 [Epub 2022 Jan 26]. Erratum in: Circulation. 2022 Sep 6;146(10):e141. 3. Ali, N, Kathak, RR, Fariha, KA, Taher, A, Islam, F. Prevalence of dyslipidemia and its associated factors among university academic staff and students in Bangladesh. BMC Cardiovasc Disord 2023;23:366. https://doi.org/10.1186/s12872-023-03399-1. 4. Jin, ES, Shim, JS, Kim, SE, Bae, JH, Kang, S, Won, JC, et al.. Committee of public relation of the Korean society of lipid and atherosclerosis. Dyslipidemia fact sheet in South Korea, 2022. J Lipid Atheroscler. 2023;12:237-51. https://doi.org/10.12997/jla.2023.12.3.237. 5. Muraleedharan, V, Jones, TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab 2010;1:207–23. https://doi.org/10.1177/2042018810390258.
|
|